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Abstract
The rise of antimicrobial resistance, coupled with a lack of industrial focus on antimicrobial
discovery over preceding decades, has brought the world to a crisis point. With both human
and animal health set to decline due to increased disease burdens caused by near untreatable
microbial pathogens, there is an urgent need to identify new antimicrobials. Central to this is
the elucidation of new, robustly validated, drug targets. Informed by industrial practice and
concerns, the use of both biological and chemical tools in validation is key. In parallel, repur-
posing approved drugs for use as antimicrobials may provide both new treatments and iden-
tify new targets, whilst improved understanding of pharmacology will help develop and
progress good ‘hits’ with the required rapidity. In recognition of the need to increase research
efforts in these areas, in 14–16 September 2017, the British Society for Parasitology (BSP)
Autumn Symposium was hosted at Durham University with the title: Microbial Protein
Targets: towards understanding and intervention. Staged in collaboration with the Royal
Society of Chemistry (RSC) Chemistry Biology Interface Division (CBID), the core aim was
to bring together leading researchers working across disciplines to imagine novel approaches
towards combating infection and antimicrobial resistance. Sessions were held on: ‘Anti-infect-
ive discovery, an overview’; ‘Omic approaches to target validation’; ‘Genetic approaches to tar-
get validation’; ‘Drug target structure and drug discovery’; ‘Fragment-based approaches to
drug discovery’; and ‘Chemical approaches to target validation’. Here, we introduce a series
of review and primary research articles from selected contributors to the Symposium, giving
an overview of progress in understanding antimicrobial targets and developing new drugs.
The Symposium was organized by Paul Denny (Durham) for the BSP and Patrick Steel
(Durham) for RSC CBID.
Introduction
The threat posed by anti-microbial resistance (AMR) has been well publicized with respect to
bacterial pathogens, and the need to identify, validate and exploit new drug targets emphasized
(Brown and Wright, 2016). However, similar pressures exist for protozoan pathogens (Tuteja,
2017; Uliana et al. 2017). The Special Issue of Parasitology introduced here is focused on glo-
bal infectious disease, namely the causative agents of the bacterial disease tuberculosis (TB;
Mycobacterium tuberculosis) and the protozoal infections malaria, toxoplasmosis, leishmania-
sis, African Sleeping Sickness and Chagas disease (the apicomplexans Plasmodium spp. and
Toxoplasma gondii; and the kinetoplastids Leishmania spp., Trypanosoma brucei sp. and
T. cruzi, respectively). Each of these poses serious challenges to health and wellbeing, and
offer a multitude of challenges to effective treatment. Responsible for 1·8 M deaths, and with
nearly 5% of the 10 million or more new cases each year showing multi-drug resistance,
M. tuberculosis remains a serious problem, particularly in low- and middle-income countries
(WHO, 2015). Similarly, although incidence levels fell more than 20% during 2010–2015,
infection with mosquito-borne Plasmodium falciparum, the causative agent of serious malaria,
remains a major global health problem leading to more than 200 M new cases and 400 000
deaths/year (WHO, 2016a). The related apicomplexan protozoa Toxoplasma, classified
by the Centers for Disease Control as causing a Neglected Parasitic Disease, chronically infects
30–60 M people in the USA alone, where it is considered a major food-borne pathogen (CDC,
2017). The kinetoplastid parasites Leishmania spp., T. cruzi and T. brucei sp. are insect-borne
causes of Neglected Tropical Diseases (NTDs). However, whilst cases for African Sleeping
Sickness caused by the later are declining [<3000 in 2015; (WHO, 2016b)], there are up to
1 M new cases of leishmaniasis per year, leading to 20 000 deaths and 6–7 M people remain
infected with the parasite that causes Chagas disease (WHO, 2017). Indeed, the battle against
Leishmania spp. and T. cruzi infection has recently been described as a losing one (Hotez and
Aksoy, 2017).
For the global infections outlined above, the available drugs have limitations of efficacy, tol-
erance and/or administration, and cases of AMR are emerging or rampant. To address these
problems, for both bacterial and protozoal pathogens there is a well recognized need to identify
new targets for antimicrobial intervention (Brown and Wright, 2016; Muller and Hemphill,
2016). However, the identification, validation and understanding of new protein targets is
not a straightforward process. For example, within the pharmaceutical industry there are wide-
spread concerns regarding the reproducibility of drug target validation studies across a range
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of disease states (Jones, 2016). Against this backdrop, the British
Society for Parasitology 2016 Autumn Symposium focused on the
identification, understanding and exploitation of targets for anti-
bacterial and anti-protozoal intervention. In recognition of the
industry concerns outlined above, the focus on cross-disciplinary
analyses of putative targets was designed to answer the call to
‘embrace chemistry at the interface with biology’ (Jones, 2016)
and provide more robustly triaged drug targets. This approach
necessitates the application of both state-of-the-art genetic and
chemical tools to answer key questions in bioscience and robustly
validate new drug targets in both bacterial and protozoan
pathogens.
Search for antimicrobial targets
With a crisis in antimicrobial resistance upon us, and the persist-
ence of neglected infectious diseases (e.g. NTDs), new drug leads
need to be rapidly identified. High-throughput screening (HTS)
remains at the centre of drug discovery and can be carried out
using either in vitro assays against validated targets or phenotypic
assays against the pathogen itself (Denny and Steel, 2014;
Norcliffe et al. 2014). Recent high content phenotypic screening
across the kinetoplastids gave a disappointingly low number of
novel potent hits against Leishmania donovani when compared
with the related parasite T. brucei (Pena et al. 2015). Phenotypic
HTS has been successfully carried out against M. tuberculosis,
for example using genetically modified bacteria in a resistance
based screen (Cox et al. 2016). However, as for the kinetoplastids
this has proven problematic, due in large part to the slow growth
rate of M. tuberculosis (White et al. 2016). These studies demon-
strated that target-based screening remains vital of for antimicro-
bial discovery and, of course, this relies upon the provision of high
quality, fully validated, antimicrobial drug targets.
Natural product antibacterials (antibiotics) targeting the
cell wall have long been in clinical use, many of these are directed
against peptidoglycan, the principle component of Gram-positive
and -negative bacterial walls (Muller et al. 2017). Such antimicro-
bials show excellent selectivity for the synthesis of this non-
mammalian structure; however, they are at the forefront of con-
cerns regarding AMR. Likewise, several anti-TB agents target
cell wall synthesis, however the M. tuberculosis wall has several
unique features, which present challenges for the development
new chemotherapeutics. For example, the long-chain mycolic
acids which cover the cell surface facilitate the intercalation of
acyl lipids forming a waxy outer membrane, which forms a hydro-
phobic barrier. Despite these obstacles the M. tuberculosis wall
and its biosynthesis remains an important and attractive target
for novel anti-TB drugs, as concluded in the first review in this
Special Issue (Abrahams and Besra, 2016). Abrahams and Besra
present the biosynthesis of this essential structural and permeabil-
ity barrier as being the ‘Achilles heel’ of this pathogen and open
up the prospect of modern approaches to drug discovery (e.g.
HTS) identifying novel therapeutics.
Similarly, the protozoan sphingolipid biosynthetic pathway has
been proposed as a possible drug target for kinetoplastid (e.g.
Leishmania spp. and T. brucei) and apicomplexan (Plasmodium
spp. and Toxoplasma) eukaryotic pathogens (Mina et al. 2010,
2011; Young et al. 2012; Coppens, 2013; Pratt et al. 2013).
Against the backdrop of ancient, toxic therapies and rising
AMR (Barrett and Croft, 2014) the essentiality of sphingolipids,
and the potential to target their biosynthesis, has seen growing
interest. In a ‘state-of-the-art’ review in this Special Issue, Mina
and Denny discuss possibilities and pitfalls of targeting this bio-
synthetic pathway, considering both parasite de novo synthesis
and host scavenging (Mina and Denny, 2017). Key differences
between the mammalian host sphingolipid biosynthetic pathway
and that of both kinetoplastid (Denny et al. 2006; Zhang et al.
2010) and apicomplexan (Coppens, 2013; Pratt et al. 2013; Mina
and Denny, 2017) protozoan parasites, have fuelled this endeavour.
In a companion piece, Alqaisi et al. (2017) describe an investigation
of the mode of action of a reported inhibitor of Toxoplasma
sphingolipid biosynthesis, aureobasidin A. However, whilst this
natural compound is antiparasitic against both acute and chronic
forms, parasite sphingolipid biosynthesis was unaffected.
Remaining in the field of lipid biochemistry, protein acylation
has long been proposed as a target of novel antiprotozoals, with
the enzyme responsible for the essential N-myristoylation of pro-
teins [N-myristoyl transferase (NMT)] identified as a potential
drug target in apicomplexan (Gunaratne et al. 2000) and kineto-
plastid (Price et al. 2003) protozoan parasites. In this Issue, the
use of chemical proteomic approaches to analyse and validate
such post-translation modifications is discussed, with reference
to both N-myristoylation and S-palmitoylation (Ritzefeld et al.
2017). The use of chemical tools (such as acyl biotin exchange
and metabolic tagging with click chemistry) is essential to fully
understand the downstream effects of enzyme inhibition and pro-
vide further validation of targets and inhibitors (Tate et al. 2014;
Ritzefeld et al. 2017).
A unique target in kinetoplastid protozoa is the mitochondrial
protein, trypanosome alternative oxidase (TAO). This target is
now well characterized in T. brucei where it has ubiquinol oxidase
activity and is expressed more than 100-fold more in pathogenic
bloodstream forms (Chaudhuri et al. 1998). Functionally it is
thought to protect the parasite from oxidative damage (Fang
and Beattie, 2003). As reviewed in this issue, inhibitors of TAO
have been identified which are able to clear infection in vivo
(Menzies et al. 2016).
Collectively, these studies and associated reviews emphasize
the place for a target-directed approach in antimicrobial discover
and emphasize the importance of chemical approaches for the
understanding and validation of drug targets.
Exploration and exploitation of antimicrobial targets
As discussed above, screening of phenotypic changes in response to
chemical assault is one approach to identifying new leads as anti-
parasitics, although obtaining informative readouts from such
assays can be complex (Denny and Steel, 2014; Norcliffe et al.
2014). In this Special Issue, the use of in silico synchronization,
using defined cell parameters, to more readily analyse the cell
cycle of T. brucei is proposed (Morriswood and Engstler, 2017).
Such an automated process could increase throughput and stand-
ardize data quantitation, perhaps providing more robust pheno-
typic data. However, if an antimicrobial target is in hand, the
search for inhibitors for use as drug leads or chemical tools for fur-
ther validation and understanding, can employ conventional HTS.
Typically, this involves screening a large, diverse compound library
(>100 k) against a protein target in a multiwell formatted biochem-
ical assay (Denny and Steel, 2014; Norcliffe et al. 2014). However,
fragment-based approaches are now often run alongside such
HTS, and have been the key to success in several drug discovery pro-
grammes (Congreve et al. 2008; Scott et al. 2012). The application of
this approach in the discoveryof inhibitors ofM. tuberculosis targets
is reviewed here by Marchetti et al. A fragment-based approach
involves screening a small library (1000–5000) of fragments
(<250 Da) against a protein target, and identifying weak binders
by using a variety of biophysical tools such as surface plasmon res-
onance and nuclear magnetic resonance (Marchetti et al. 2016).
Notable successes include the identification, using thermal shift
assays, of fragments binding to EthR, a TetR-type transcriptional
repressor that underlies M. tuberculosis resistance to the second-
line drug ethionamide (Villemagne et al. 2014). Following analyses
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of an X-ray co-crystal structure, a virtual library was designed and
screened in silico, leading to the identification of derivatives with
high in vitro activity (Tatum et al. 2013; Villemagne et al. 2014).
This demonstrates the centrality of high resolution protein struc-
tures to fragment-based ligand-discovery approaches (Murray
and Blundell, 2010), and the potential of in silico screening.
Such structure-based approaches can be considered as applic-
able to all protein targets, in this Issue the calcium-dependent
protein kinases (CDPK) from Toxoplasma are considered as tar-
gets for such an approach (Cardew et al. 2017). CDPK are
restricted to plants and protozoa and have been genetically
demonstrated to be essential in multiple systems, including
Toxoplasma, presenting them as attractive drug targets (Long
et al. 2016; Wang et al. 2016). Structure-based approaches have
led to the discovery of potent CDPK inhibitors, with specificity
with respect to mammalian kinases and good antiparasitic activity
(Lourido et al. 2013; Zhang et al. 2014; Moine et al. 2015).
This work, taken together, illustrates the power of utilising
diverse chemical and biophysical approaches to identify novel
inhibitors and antimicrobial lead compounds.
Alternative approaches and downstream necessity
Whilst target-based approaches to antimicrobial discovery remain
central, the exceedingly long history of repurposing drugs for use
as antiparasitics demonstrates that we should not be too narrow in
our thinking. As reviewed in this Special Issue repurposing has
the potential to significantly reduce the costs of antimicrobial dis-
covery by bypassing the initial development phases necessary for
new chemical entities (Charlton et al. 2017). Charlton et al. dis-
cuss the current prominence of such drugs in the treatment of
leishmaniasis, for example amphotericin B, which was developed
as an antifungal but is currently in use in the South Asian visceral
leishmaniais elimination programme (Gurunath et al. 2014). In
addition, they review the history and potential of other drugs
developed as, for example, antiviral and anticancer agents, for
use as antileishmanials. However, as Charlton et al. recognize,
whilst the discovery and repurposing of existing pharmaceuticals
will save time and money in the vital search for safe, effective and
affordable antileishmanials, the identification of the mode of
action of such drugs is essential of further development
(Ritzefeld et al. 2017).
The discovery and validation of antimicrobial targets and potent
inhibitors is, of course, a vital component of a drug discovery pro-
gramme. However, these in vitro approaches provide no indication
as to the ability of identified chemical entities to reach the target
pathogen within the host. The particularly acute challenges of
this stage in the discovery pipeline for pathogens sequestered
within host cells, such as Leishmania spp. and M. tuberculosis, is
reviewed in this Issue (Croft, 2017). The integration of pharmaco-
kinetics (PK), pharmacodynamics (PD) and physiological-
modelling into the antimicrobial drug discovery process has been
previously reviewed (Edginton et al. 2008; Nielsen and Friberg,
2013), and the importance of PK–PD analyses in M. tuberculosis
drug design demonstrated (Davies and Nuermberger, 2008;
Dartois, 2014). Given that Leishmania spp. occupy a similar intra-
cellular site to M. tuberculosis, Croft considers the application of
these approaches to antileishmanial discovery, concluding that uni-
form approaches at all levels of the pipeline are vital to ensure the
development process can proceed as rapidly as possible.
Concluding remarks
The collection within this Special Issue illustrates the centrality of
high quality target validation (using both biological and physical
methodologies); the importance of multifaceted inhibitor
discovery (integrating HTS and biophysical approaches); and
the requirement to consider physiological factors (such as PK–
PD) in antimicrobial discovery. In summary, the adoption of
the multidisciplinary approaches outlined is essential to accelerate
the discovery of new drugs to treat the most prevalent, and often
intractable, global infections caused by both bacterial and proto-
zoal pathogens.
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